登录新浪财经APP 搜索【信披】查看更多考评等级 根据《黑龙江创达集团有限公司2023年面向专业投资者非公开发行可交换公司债券（第一期）募集说明 书》（以下简称"《第一期募集说明书》"）的约定，"在本期可交换公司债券换股期内当标的股票在任 意连续30个交易日中至少10个交易日的收盘价低于10元/股时，本期可交换债券的换股价格自动向下修 正。修正后的换股价格为触发可交换债券自动下修条件之日前一交易日标的股票收盘价的90%。" "23创01EB"换股期为2023年10月12日至2026年4月11日。2026年2月4日至2026年2月25日，标的股票出 现了在换股期内连续30个交易日中已有10个交易日的收盘价低于10元/股的情况，触发《第一期募集说 明书》约定的换股价格自动下修条款。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 按照《第一期募集说明书》的相关约定，"23创01EB"的换股价格将从7.75元/股自动下修至7.30元/股， 调整后的换股价格将于2026年3月2日生效。本次换股价格下修后，创达集团本期可交债质押专户中预 ...

证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-012 黑龙江珍宝岛药业股份有限公司 "23 创 01EB"换股期为 2023 年 10 月 12 日至 2026 年 4 月 11 日。2026 年 2 月 4 日至 2026 年 2 月 25 日，标的股票出现了在换股期内连续 30 个交易日中已 有 10 个交易日的收盘价低于 10 元/股的情况，触发《第一期募集说明书》约定 的换股价格自动下修条款。 按照《第一期募集说明书》的相关约定，"23 创 01EB"的换股价格将从 7.75 元/股自动下修至 7.30 元/股，调整后的换股价格将于 2026 年 3 月 2 日生效。本 近日，黑龙江珍宝岛药业股份有限公司（以下简称"公司"）收到公司控股 股东黑龙江创达集团有限公司（以下简称"创达集团"）的通知，创达集团 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第一期可 交债"）换股价格将进行调整，现将有关事项公告如下： 一、控股股东可交换公司债券的基本情况 公司控股股东创达集团已于 2023 年 4 月 11 日完成第一期可交债的发行。本 期可交债简称"23 创 0 ...

证券日报网讯 2月26日，珍宝岛在互动平台回答投资者提问时表示，公司截至2026年2月13日A股股东人 数为29081户。 （文章来源：证券日报） ...

证券日报网讯 2月24日，珍宝岛在互动平台回答投资者提问时表示，公司截至2026年2月10日A股股东人 数为29297户。 （文章来源：证券日报） ...

格隆汇2月24日丨珍宝岛(603567.SH)跌0.37%，报8.100元，股价创历史新低，总市值76.22亿元。 ...

五成公司预告盈利药明康德、三生国健等预盈超10亿 以业绩预告净利润下限统计，已公布2025年业绩预告的274家医药生物上市公司中，137家预计实现盈利，占比五成。 其中，10家公司预告归母净利润超10亿元，包括药明康德、三生国健、吉林敖东等。 新华财经北京2月24日电截至2026年2月12日，根据申万行业分类，A股医药生物行业逾500家上市公司，其中约274家已披露2025年业绩预告。 整体来看，已披露2025年业绩预告的274家医药生物上市公司中，业绩偏正面（包括预增、略增、扭亏及续盈）的企业合计90家。 137家医药生物上市公司2025年实现盈利，占比50%，其中10家归母净利润超10亿元。 图1：A股医药生物行业上市公司2025年业绩预告类型 图3：药明康德2025年度业绩预告 | | 2025年预告利润超过10亿元 | | | --- | --- | --- | | 证券代码 | 证券简称 | 业绩预告类型 | | 603259.SH | 药明康德 | 预增 | | 688336.CH | 三生国健 | 预增 | | 000623.SZ | 吉林敖东 | 预增 | | 688578.SH | 艾力斯 ...

Group 1 - The company, Zhenbao Island, announced a forecast for 2025 indicating a net profit loss of between 1.012 billion to 1.173 billion yuan, marking its first annual loss since its listing, primarily due to delayed procurement of traditional Chinese medicine and healthcare cost control, leading to a 53% year-on-year revenue decline and a 93% drop in gross profit [1] - Revenue has continuously declined from a peak of 4.219 billion yuan in 2022, with only 919 million yuan reported in the first three quarters of 2025, representing a 54.73% year-on-year decrease, while the net profit excluding non-recurring items has turned negative multiple times since 2022, indicating weakened core profitability [1] - The company's investment in innovative drug research and development is progressing slowly, making it difficult to support performance in the short term [1] Group 2 - The stock price of Zhenbao Island has experienced a continuous decline over the past seven days, with a total drop of 3.91%, closing at 8.12 yuan on February 12, down 1.81% for the day, and showing a net outflow of 11.388 million yuan in principal funds on the same day, with retail investors accounting for 36% [2] - Technical analysis indicates that the stock is in a bearish trend, with the moving average system showing a bearish arrangement, a resistance level at 9.33 yuan, and a support level at 7.96 yuan, underperforming compared to the pharmaceutical and biological sector and the broader market [2] Group 3 - On February 6, 2026, the controlling shareholder, Chuangda Group, announced a reduction in its shareholding from 56.98% to 55.86% due to the conversion of exchangeable bonds, although control has not changed [3] - As of February 10, Chuangda Group has pledged 80.48% of its shares, with an additional 1.17 million shares pledged to secure the exchangeable bond guarantee [3] - On February 6, the Ministry of Industry and Information Technology and other departments released the "High-Quality Development Plan for Traditional Chinese Medicine Industry (2026-2030)," emphasizing the upgrade of the entire industry chain, which aligns with Zhenbao Island's layout, but the short-term impact on performance is limited [3]

Core Viewpoint - The traditional Chinese medicine company Zhenbaodao Pharmaceutical is expected to report a net loss of between 1.012 billion and 1.173 billion yuan for the fiscal year 2025, marking its first annual loss since its listing in 2015, nearly erasing the total net profit from the previous three years [1][10] Financial Performance - The company's revenue peaked at 4.219 billion yuan in 2022 but plummeted by 25.5% to 3.144 billion yuan in 2023, with a further decline of 13.84% to 2.707 billion yuan in 2024, falling below 2018 levels. In the first three quarters of 2025, revenue dropped by 54.73% to only 919 million yuan, indicating a trend towards a historical low for the year [2][11] - The net profit, excluding non-recurring gains and losses, turned negative for the first time in 2022, with a loss of 280 million yuan. Although the loss narrowed to 31.84 million yuan in 2023, the downward trend continued, with an expected loss of between 1.073 billion and 1.234 billion yuan in 2025 [4][13] Asset Structure and Risks - The company faces significant asset structure risks, with accounts receivable reaching 3.111 billion yuan by the end of September 2025, while revenue for the same period was only 919 million yuan, resulting in a ratio of accounts receivable to revenue of 338.52%. This ratio has been on the rise in recent years [4][13] - Inventory levels surged from 1.005 billion yuan in Q3 2023 to 1.521 billion yuan in Q3 2025, reflecting a more than 50% year-on-year increase, indicating severe sales obstacles and inventory accumulation issues [4][13] Operational Efficiency - The company's operational efficiency has deteriorated, with inventory turnover days and accounts receivable turnover days reaching historical highs of 692.31 days and 919.37 days, respectively, more than doubling compared to the previous year [5][14] Impairment Losses - Zhenbaodao plans to recognize approximately 395 million yuan in credit impairment losses and about 266 million yuan in asset impairment losses, with these combined losses exceeding 660 million yuan, significantly impacting annual performance [7][16] Business Challenges - Core products have been included in the national centralized procurement of traditional Chinese medicine, coupled with increased pressure from national medical insurance cost control, leading to significant price reductions. The anticipated volume increase through price reductions has not materialized, resulting in a decline in both volume and price [7][16] Research and Development - Despite attempts to explore new growth avenues, the company has significantly reduced R&D investments, with R&D expenses dropping by 52.64% to 37.99 million yuan in 2024, accounting for only 2.60% of revenue, far below industry leaders [8][17] - The company announced plans to invest over 400 million yuan in building an R&D platform for innovative drugs, but actual investment progress has been slow, with only 92.17 million yuan spent by mid-2025, representing 26.26% of the planned investment [8][17] Dividend Policy and Governance Issues - Zhenbaodao has maintained a rigid cash dividend policy, distributing a total of 1.302 billion yuan since its listing, despite deteriorating fundamentals. In 2023 and 2024, the company distributed 188 million yuan and 141 million yuan, respectively [9][18] - The concentrated ownership structure raises concerns, as the largest beneficiary of dividends is the controlling shareholder, with a high pledge ratio of 81% for the controlling shareholder's equity, increasing financial risks [9][18] - Governance issues were highlighted by a lack of proper procedures in a significant 425 million yuan subsidiary equity transfer, exposing internal control deficiencies [10][19] Conclusion - Zhenbaodao Pharmaceutical is facing severe challenges due to industry changes, internal governance issues, and actions by major shareholders, necessitating a balance between short-term returns and long-term development to restore fundamentals and rebuild market trust [10][19]

Core Viewpoint - The announcement details a change in the equity structure of Heilongjiang Zhenbaodao Pharmaceutical Co., Ltd. due to the passive reduction of shares held by its controlling shareholder, Heilongjiang Chuangda Group Co., Ltd., following the conversion of exchangeable bonds [2][3]. Group 1: Equity Change Overview - After the equity change, Heilongjiang Chuangda Group holds 516,973,085 shares, representing 54.94% of the total share capital of Zhenbaodao [2][3]. - The equity change is a result of the conversion of exchangeable bonds issued by Chuangda Group, leading to a decrease in its shareholding from 55.86% to 54.94% [3][4]. Group 2: Details of the Equity Change - From February 5 to February 9, 2026, a total of 8,709,675 shares were converted, accounting for approximately 0.93% of the total share capital [4][11]. - The equity change does not trigger a mandatory tender offer and will not alter the controlling shareholder or actual controller of the company [2][5]. Group 3: Future Plans and Compliance - Chuangda Group's exchangeable bonds are currently in the conversion period, and the company will continue to monitor the conversion activities [5][8]. - The company has committed to fulfilling its information disclosure obligations in accordance with relevant laws and regulations [5][8].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：603567 证券简称：珍宝岛 公告编号：临 2026-011 黑龙江珍宝岛药业股份有限公司 关于控股股东权益变动的提示性公告 本次权益变动后，黑龙江创达集团有限公司（以下简称"创达集团"）持有黑 龙江珍宝岛药业股份有限公司（以下简称"公司"或"珍宝岛"）股份 516,973,085 股，占公司总股本的 54.94%。 本次权益变动属于创达集团发行的可交换公司债券持有人换股造成权益变动 人被动减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 一、本次权益变动基本情况 公司于近日收到控股股东创达集团的《简式权益变动报告书》，获悉创达集团发 行的 2023 年面向专业投资者非公开发行可交换公司债券（第一期）（以下简称"第 一期可交换债券"）和 2023 年面向专业投资者非公开发行可交换公司债券（第二期） （以下简称"第二期可交换债券"）的债券持有人发生换股，导致创达集团持股比例 被动下降，持有公司股份比例从 55.86%减少至 54.94%， ...